These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 15720212)

  • 21. Brain urea increase is an early Huntington's disease pathogenic event observed in a prodromal transgenic sheep model and HD cases.
    Handley RR; Reid SJ; Brauning R; Maclean P; Mears ER; Fourie I; Patassini S; Cooper GJS; Rudiger SR; McLaughlan CJ; Verma PJ; Gusella JF; MacDonald ME; Waldvogel HJ; Bawden CS; Faull RLM; Snell RG
    Proc Natl Acad Sci U S A; 2017 Dec; 114(52):E11293-E11302. PubMed ID: 29229845
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cognitive Dysfunction in Huntington's Disease: Humans, Mouse Models and Molecular Mechanisms.
    Giralt A; Saavedra A; Alberch J; Pérez-Navarro E
    J Huntingtons Dis; 2012; 1(2):155-73. PubMed ID: 25063329
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic Strategies for Huntington's Disease.
    Mrzljak L; Munoz-Sanjuan I
    Curr Top Behav Neurosci; 2015; 22():161-201. PubMed ID: 24277342
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mitochondrial fragmentation in neuronal degeneration: Toward an understanding of HD striatal susceptibility.
    Cherubini M; Ginés S
    Biochem Biophys Res Commun; 2017 Feb; 483(4):1063-1068. PubMed ID: 27514446
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased Steady-State Mutant Huntingtin mRNA in Huntington's Disease Brain.
    Liu W; Chaurette J; Pfister EL; Kennington LA; Chase KO; Bullock J; Vonsattel JP; Faull RL; Macdonald D; DiFiglia M; Zamore PD; Aronin N
    J Huntingtons Dis; 2013; 2(4):491-500. PubMed ID: 25062733
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Animal models of Huntington's disease: implications in uncovering pathogenic mechanisms and developing therapies.
    Wang LH; Qin ZH
    Acta Pharmacol Sin; 2006 Oct; 27(10):1287-302. PubMed ID: 17007735
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical Aspects of Huntington's Disease.
    Ghosh R; Tabrizi SJ
    Curr Top Behav Neurosci; 2015; 22():3-31. PubMed ID: 23975844
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting CAG repeat RNAs reduces Huntington's disease phenotype independently of huntingtin levels.
    Rué L; Bañez-Coronel M; Creus-Muncunill J; Giralt A; Alcalá-Vida R; Mentxaka G; Kagerbauer B; Zomeño-Abellán MT; Aranda Z; Venturi V; Pérez-Navarro E; Estivill X; Martí E
    J Clin Invest; 2016 Nov; 126(11):4319-4330. PubMed ID: 27721240
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting mutant huntingtin for the development of disease-modifying therapy.
    Appl T; Kaltenbach L; Lo DC; Terstappen GC
    Drug Discov Today; 2012 Nov; 17(21-22):1217-23. PubMed ID: 22772050
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Donor age dependent graft development and recovery in a rat model of Huntington's disease: histological and behavioral analysis.
    Schackel S; Pauly MC; Piroth T; Nikkhah G; Döbrössy MD
    Behav Brain Res; 2013 Nov; 256():56-63. PubMed ID: 23916743
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transplanted fetal striatum in Huntington's disease: phenotypic development and lack of pathology.
    Freeman TB; Cicchetti F; Hauser RA; Deacon TW; Li XJ; Hersch SM; Nauert GM; Sanberg PR; Kordower JH; Saporta S; Isacson O
    Proc Natl Acad Sci U S A; 2000 Dec; 97(25):13877-82. PubMed ID: 11106399
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rationale for intrastriatal grafting of striatal neuroblasts in patients with Huntington's disease.
    Peschanski M; Cesaro P; Hantraye P
    Neuroscience; 1995 Sep; 68(2):273-85. PubMed ID: 7477940
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selective degeneration in YAC mouse models of Huntington disease.
    Van Raamsdonk JM; Warby SC; Hayden MR
    Brain Res Bull; 2007 Apr; 72(2-3):124-31. PubMed ID: 17352936
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Biology of Huntingtin.
    Saudou F; Humbert S
    Neuron; 2016 Mar; 89(5):910-26. PubMed ID: 26938440
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recent insights into the molecular pathogenesis of Huntington disease.
    Leavitt BR; Wellington CL; Hayden MR
    Semin Neurol; 1999; 19(4):385-95. PubMed ID: 10716661
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cell therapy in Huntington disease.
    Clelland CD; Barker RA; Watts C
    Neurosurg Focus; 2008; 24(3-4):E9. PubMed ID: 18341412
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The mGluR5 positive allosteric modulator, CDPPB, ameliorates pathology and phenotypic signs of a mouse model of Huntington's disease.
    Doria JG; de Souza JM; Andrade JN; Rodrigues HA; Guimaraes IM; Carvalho TG; Guatimosim C; Dobransky T; Ribeiro FM
    Neurobiol Dis; 2015 Jan; 73():163-73. PubMed ID: 25160573
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Challenges in progressing cell therapies to the clinic for Huntington's disease: A review of the progress made with pluripotent stem cell derived medium spiny neurons.
    Garcia Jareño P; Bartley OJM; Precious SV; Rosser AE; Lelos MJ
    Int Rev Neurobiol; 2022; 166():1-48. PubMed ID: 36424090
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.